Table 1 Baseline clinical characteristics of study population
Variables | CAE group | CAD group | Control group | p value |
|---|---|---|---|---|
(n = 113) | (n = 144) | (n = 157) | ||
Age (years) | 48±10 | 57±18 | 54±13 | 0.036 |
Sex (F/M) | 97/16 | 110/34 | 121/36 | 0.044 |
BMI (kg/m2) | 24±4 | 24±3 | 24±4 | 0.748 |
Family history of CAD, n (%) | 16 (14) | 31 (22) | 30 (19) | 0.270 |
Current smoker, n (%) | 48 (43) | 32 (22) | 15 (10) | 0.041 |
Hypertension, n (%) | 34 (31) | 39 (27) | 31 (20) | 0.035 |
Hyperlipidemia, n (%) | 31 (27) | 40 (28) | 53 (34) | 0.509 |
Diabetes, n (%) | 13 (12) | 22 (15) | 20 (13) | 0.713 |
LVEF (%) | 58±6 | 61±8 | 60±7 | 0.824 |
Medications on admission | ||||
Aspirin, n (%) | 52 (46) | 60 (42) | 58 (37) | 0.192 |
β-blocke, n (%) | 25 (22) | 30 (21) | 29 (19) | 0.307 |
ACEI/ARB, n (%) | 22 (20) | 33 (23) | 27 (17) | 0.316 |
Statin, n (%) | 17 (15) | 22 (16) | 19 (12) | 0.818 |
CCB, n (%) | 9 (8) | 14 (10) | 14 (9) | 0.934 |